Aligos Therapeutics (NASDAQ:ALGS) Shares Down 4.5% – Time to Sell?

Aligos Therapeutics, Inc. (NASDAQ:ALGS)’s share price fell 4.5% on Monday . The company traded as low as $9.33 and last traded at $9.65. 57,630 shares traded hands during trading, a decline of 18% from the average session volume of 70,298 shares. The stock had previously closed at $10.11.

Wall Street Analyst Weigh In

ALGS has been the topic of a number of analyst reports. Wall Street Zen cut Aligos Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a research note on Wednesday, October 8th. Finally, HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Aligos Therapeutics in a report on Friday, September 12th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $50.00.

Aligos Therapeutics Stock Performance

The company’s fifty day moving average price is $9.26 and its two-hundred day moving average price is $9.18. The firm has a market capitalization of $57.32 million, a PE ratio of -0.47 and a beta of 2.74.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Thursday, November 6th. The company reported ($3.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.09) by ($0.95). Aligos Therapeutics had a negative return on equity of 39.35% and a negative net margin of 3,267.65%.The company had revenue of $0.74 million for the quarter, compared to analyst estimates of $0.50 million. On average, equities analysts expect that Aligos Therapeutics, Inc. will post -10.36 earnings per share for the current year.

Institutional Trading of Aligos Therapeutics

A number of large investors have recently bought and sold shares of the stock. NorthCrest Asset Manangement LLC acquired a new position in Aligos Therapeutics during the 3rd quarter valued at about $98,000. Susquehanna International Group LLP acquired a new position in shares of Aligos Therapeutics during the 3rd quarter worth approximately $99,000. XTX Topco Ltd bought a new stake in Aligos Therapeutics in the 2nd quarter valued at $100,000. AlphaQuest LLC bought a new stake in shares of Aligos Therapeutics during the 1st quarter valued at $130,000. Finally, Geode Capital Management LLC raised its holdings in shares of Aligos Therapeutics by 21.3% during the 2nd quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock worth $246,000 after buying an additional 5,978 shares in the last quarter. 60.43% of the stock is currently owned by institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.